Cargando…

Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial‐05 (JOINT‐05)

Associations between urinary pentosidine, one of the advanced glycation end products in collagen, and the risk of fracture in patients with severe osteoporosis are unknown. In this study, we investigated whether the urinary pentosidine level is associated with the incidence of morphometric vertebral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Shiro, Saito, Mitsuru, Hagino, Hiroshi, Mori, Satoshi, Nakamura, Toshitaka, Ohta, Hiroaki, Sone, Teruki, Takahashi, Kaito, Mitomo, Yuji, Sugimoto, Toshitsugu, Soen, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549726/ https://www.ncbi.nlm.nih.gov/pubmed/36248273 http://dx.doi.org/10.1002/jbm4.10673

Ejemplares similares

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
por: Mori, Satoshi, et al.
Publicado: (2022)

A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05
por: Hagino, H., et al.
Publicado: (2021)

Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene
por: Ohta, Hiroaki, et al.
Publicado: (2023)

Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary
por: Orimo, Hajime, et al.
Publicado: (2012)

Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study
por: Matsumoto, Toshio, et al.
Publicado: (2022)

Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study
por: Shiraki, Masataka, et al.
Publicado: (2021)

24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
por: Sugimoto, Toshitsugu, et al.
Publicado: (2017)

P05 Osteoporosis in thalassemia; a case with multifactorial aetiology
por: Rosa, Chamith, et al.
Publicado: (2023)

Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis
por: Nakamura, Toshitaka, et al.
Publicado: (2013)

New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide
por: Tanaka, Sakae, et al.
Publicado: (2014)

A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis
por: Soen, Satoshi, et al.
Publicado: (2020)

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis
por: Sone, Teruki, et al.
Publicado: (2017)

Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
por: Nakamura, Toshitaka, et al.
Publicado: (2014)

Pentosidine Accumulation in Human Oocytes and Their Correlation to Age-Related Apoptosis
por: Matsumine, Miki, et al.
Publicado: (2008)

Genetic risk score based on the prevalence of vertebral fracture in Japanese women with osteoporosis
por: Zhou, Heying, et al.
Publicado: (2016)

Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis
por: Yoo, Jun-Il, et al.
Publicado: (2017)

Osteoporosis liaison service in Japan
por: Hagino, Hiroshi, et al.
Publicado: (2019)

Three years of treatment with minodronate in patients with postmenopausal osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2011)

EXM-86-05: 07/05/1986
por: Malandain, E
Publicado: (1986)

Plasma pentosidine as a useful biomarker of sarcopenia, low gait speed, and mortality in patients with cirrhosis
por: Saeki, Chisato, et al.
Publicado: (2023)

Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
por: Nakamura, T., et al.
Publicado: (2016)

Glucuronic acid is a novel source of pentosidine, associated with schizophrenia
por: Toriumi, Kazuya, et al.
Publicado: (2023)

Plasma pentosidine levels are associated with prevalent fractures in patients with chronic liver disease
por: Saeki, Chisato, et al.
Publicado: (2021)

Microstructural Design of Ba(0.5)La(0.5)Co(0.5)Fe(0.5)O(3) Perovskite Ceramics
por: Gierszewska, Daria, et al.
Publicado: (2021)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

Utility of radius bone densitometry for the treatment of osteoporosis with once-weekly teriparatide therapy
por: Nakayama, Harumi, et al.
Publicado: (2018)

Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis
por: Okazaki, R., et al.
Publicado: (2011)

Exchange bias effect in polycrystalline Bi(0.5)Sr(0.5)Fe(0.5)Cr(0.5)O(3) bulk
por: Li, S. Z., et al.
Publicado: (2023)

Responsiveness of the Japanese Osteoporosis Quality of Life questionnaire in women with postmenopausal osteoporosis
por: Urushihara, Hisashi, et al.
Publicado: (2014)

Structural Insight into La(0.5)Ca(0.5)Mn(0.5)Co(0.5)O(3) Decomposition in the Methane Combustion Process
por: Nikolaeva, Olga, et al.
Publicado: (2021)

Crystal chemistry and compressibility of Fe(0.5)Mg(0.5)Al(0.5)Si(0.5)O(3) and FeMg(0.5)Si(0.5)O(3) silicate perovskites at pressures up to 95 GPa
por: Koemets, Iuliia, et al.
Publicado: (2023)

Pentosidine and carboxymethyl-lysine associate differently with prevalent osteoporotic vertebral fracture and various bone markers
por: Nakano, Masaki, et al.
Publicado: (2020)

Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2012)

Near-infrared emitting CdTe(0.5)Se(0.5)/Cd(0.5)Zn(0.5)S quantum dots: synthesis and bright luminescence
por: Yang, Ping, et al.
Publicado: (2012)

Especificación para estructuras de mampostería (ACI 530.1-05/ASCE 6-05/TMS 602-05)
Publicado: (2007)

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020)

Common Variants in a Novel Gene, FONG on Chromosome 2q33.1 Confer Risk of Osteoporosis in Japanese
por: Kou, Ikuyo, et al.
Publicado: (2011)

ICIS05 CONFERENCE
por: Lau, C, et al.
Publicado: (02/1)

EXM 82.05
Publicado: (1982)

PCM 89-05
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_3accsrec67953v02ceflnttnj2